Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.45 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.42 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.42 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.40 |
| ▸ | BMP1 | P13497 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30930177 | 0.93 | GLO1 (0.42) | GNPATFOLH1NAALAD2RIMKLANOD1 | |
| SCHEMBL31674464 | 0.92 | GNPAT (0.43) | GNPATENPEPPTGS1GSTK1 | |
| SCHEMBL29352968 | 0.91 | FOLH1 (0.41) | GNPATFOLH1NAALAD2RIMKLANOD1 | |
| SCHEMBL31332141 | 0.91 | FOLH1 (0.41) | GNPATFOLH1NAALAD2RIMKLANOD1 | |
| SCHEMBL9348762 | 0.89 | FOLH1 (0.43) | FOLH1NAALAD2RIMKLANOD1GLO1 | |
| SCHEMBL9348776 | 0.89 | FOLH1 (0.43) | FOLH1NAALAD2RIMKLANOD1GLO1 | |
| SCHEMBL29575351 | 0.88 | GNPAT (0.52) | GNPATENPEPFOLH1NAALAD2RIMKLA | |
| SCHEMBL29695576 | 0.86 | ENPEP (0.42) | ENPEPKEAP1BACE1 | |
| SCHEMBL10437934 | 0.86 | NOD1 (0.44) | FOLH1NOD1GLO1BMP1PTGS1 | |
| SCHEMBL10437933 | 0.86 | NOD1 (0.44) | FOLH1NOD1GLO1BMP1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713364-A1 | MODIFIED SINGLE-DOMAIN ANTIBODIES | ODYSSEY THERAPEUTICS, INC. (US) | 2026-03-25 | — | — | EP | claimed |
| US-12497609-B2 | Protospacer adjacent motif sequence and method for modifying target nucleic acid in genome of cell by using same | YONSEI UNIVERSITY BIOHEALTH TECHNOLOGY HOLDINGS. INC. (KR) | 2025-12-16 | — | — | US | claimed |
| WO-2024238790-A1 | MODIFIED SINGLE-DOMAIN ANTIBODIES | ODYSSEY THERAPEUTICS, INC. (US) | 2024-11-21 | — | — | WO | claimed |
| US-20230074760-A1 | NOVEL PROTOSPACER ADJACENT MOTIF SEQUENCE AND METHOD FOR MODIFYING TARGET NUCLEIC ACID IN GENOME OF CELL BY USING SAME | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2023-03-09 | — | — | US | claimed |
| CN-114555803-A | Prespacer sequence adjacent motif sequence and method for modifying target nucleic acid in cell genome by using the same | 延世大学校产学协力团 | 2022-05-27 | — | — | CN | claimed |
| CN-115335392-B | Inhibition of shade-avoidance response in plants | 成对植物服务股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4713364-A1 | MODIFIED SINGLE-DOMAIN ANTIBODIES | ODYSSEY THERAPEUTICS, INC. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12576137-B2 | Collagen hydrolysate comprising GPCR ligand peptide | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2026-03-17 | — | — | US | disclosed |
| US-12497609-B2 | Protospacer adjacent motif sequence and method for modifying target nucleic acid in genome of cell by using same | YONSEI UNIVERSITY BIOHEALTH TECHNOLOGY HOLDINGS. INC. (KR) | 2025-12-16 | — | — | US | disclosed |
| WO-2025229160-A1 | ENGINEERED PROTEINS THAT ENGAGE COMPLEMENT FACTOR AND A PROTEIN ANTIGEN, METHODS, AND USES THEREOF | COMMIT BIOLOGICS APS (DK) | 2025-11-06 | — | — | WO | disclosed |
| CN-114555817-B | Rhamnose polysaccharide | 敦提大学 | 2025-06-10 | — | — | CN | disclosed |
| CN-113710807-B | Microorganisms and methods for producing oxygenates from hexoses | 布拉斯科公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-114073775-A | Combination therapy for delivery across the blood brain barrier | 比奥阿赛斯技术有限公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-112080516-B | Application and method of BRI1 in plant immune signal verification | 四川农业大学 | 2022-02-15 | — | — | CN | disclosed |
| CN-114026116-A | RAS neoantigen specific binding proteins and uses thereof | 弗雷德哈钦森癌症研究中心 | 2022-02-08 | — | — | CN | disclosed |
| CN-114008197-A | Metabolic engineering for simultaneous consumption of xylose and glucose to produce chemicals from second generation sugars | 布拉斯科公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-113999271-A | Simple method for extracting 5' -cytidylic acid from microbial fermentation broth | 江苏香地化学有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-113993550-A | Conditioning method for gene therapy | 美真达治疗公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-113975386-A | Treatment of eosinophil or mast cell related disorders | 塞尔德克斯医疗公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-113968901-A | Use of protein sequences that bind to substrates for the preparation of products inhibiting fibrin assembly | 南京大学 | 2022-01-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576137-B2 | Collagen hydrolysate comprising GPCR ligand peptide | GPR35, GPR39, VIP | GNPAT 4096/4885ENPEP 458/4885FOLH1 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.